Galderma has launched Sculptra (poly-L-lactic acid) in India, marking the company's entry into the regenerative aesthetics segment in one of Asia's fastest-growing aesthetic markets. Sculptra is a FDA-cleared biostimulator that stimulates collagen production over time, with results visible over 3–6 months and lasting up to 2 years.
Injectables
Galderma Launches Sculptra in India—Regenerative Expansion
Poly-L-lactic acid biostimulator enters India market as Galderma builds APAC footprint.
India's aesthetic market expands 15%+ annually; biostimulators command higher margins.
The India launch reflects Galderma's strategy to diversify beyond its core dermal filler and toxin portfolio into longer-acting, higher-margin biostimulators. India's aesthetic market is expanding at 15%+ annually, driven by rising disposable income and social-media-driven demand. Sculptra's mechanism—collagen induction rather than volume replacement—appeals to practitioners seeking differentiation and to patients willing to invest in multi-session protocols. Galderma's distribution network and regulatory relationships position it to capture share ahead of smaller competitors in a market where brand trust and supply reliability are critical.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.